not detect a Bence-Jones protein. Total IgE level was elevated at 322 200 kU/L in the absence of atopy or recurrent infections. Stool and serological examinations failed to demonstrate the presence of parasites. There was no peripheral eosinophilia, with normal tryptase results. Serum amyloid A was elevated at 120 mg/L (0.0-6.4).
A trephine biopsy revealed a moderately hypercellular marrow with plasma cells accounting for less than 5% of total nucleated cells. Analyses for JAK2, c-KIT, BCR-ABL and PDGFR mutations revealed no abnormalities. Amyloid deposits were not evident on bone marrow and endoscopic biopsy specimens. CT imaging of the chest, abdomen and pelvis did not show an occult lesion. Therefore, the most likely explanation for the IgE kappa paraprotein is a monoclonal gammopathy of undetermined significance (MGUS).
IgE monoclonal gammopathy is an extremely rare condition, with less than fifty cases reported in the literature. This case highlights the importance of screening for monoclonal epsilon and delta heavy chain when an isolated light chain band is detected on a routine immunofixation. This is the first described case of IgE MGUS in a patient with FMF. It remains unclear as to whether these two disease processes are occurring as separate, yet concurrent entities, or are pathologically interrelated. A 23-year-old international student from Hong Kong, presented to hospital with a six week history of spontaneous left lower limb pain and swelling. Her mobility had gradually declined to the point that she was wheelchairdependent.
The patient had a history of nephrotic syndrome in 2004, managed in Hong Kong. Initial renal biopsies were consistent with minimal change disease but follow-up biopsies in 2006 showed focal segmental glomerulosclerosis (FSGS). The renal disease was refractory to steroids, and she had received further treatment with cyclosporine, cyclophosphamide, rituximab and ongoing tacrolimus, mycophenolate mofetil and low dose prednisolone.
The patient's leg swelling was not associated with systemic symptoms. Examination revealed non-pitting oedema, warmth and exquisite tenderness of the left calf. Pulses and capillary refill was normal. Inflammatory markers were elevated. Renal function and urinalysis was normal. A lower limb Doppler ultrasound was normal. MRI revealed diffuse muscle oedema suggestive of myositis. A muscle biopsy showed no evidence of significant muscle inflammation but necrotizing inflammation of medium blood vessels with fibrinoid necrosis. Autoimmune, myositis, vasculitic, infective and thrombotic screens were negative. A CT angiogram was reported as normal. The patient was commenced on pulse methylprednisolone and discharged on high dose prednisolone. She had a rapid symptomatic response, with resolution of muscle pain and ability to mobilise normally.
Our impression was of probable polyarteritis nodosa (PAN), localised to the limb. We questioned whether her initial renal disease may also have been explained by PAN with secondary FSGS. Rituximab was recommended for ongoing disease control. We report the first case of methaemoglobinaemia caused by omalizumab. Having suffered for 3 years from treatment-refractory chronic idiopathic urticaria, resistant to high dose antihistamines, montelukast, dapsone and frequent bursts of systemic corticosteroids, a 50-year-old female patient presented for a graded challenge of omalizumab, the humanised monoclonal antibody targeting immunoglobulin E (IgE).
She had previously received 150 mg subcutaneous omalizumab monthly for a nine month period with a near complete clinical response. However, light-headedness around 8 h after each injection prompted discontinuation. Recurrence of urticaria and its associated poor quality of life inspired a graded challenge scheduled over three days (Day 1 -50 mg, Day 2 -100 mg, Day 3 -150 mg).
Eight hours after the second dose of omalizumab our patient became symptomatic with a headache and light-headedness. Cyanosis coupled with hypoxia, that failed to correct with supplemental oxygen prompted an arterial blood gas, which identified methaemoglobinaemia (27%, normal range 0-2%). The patient was treated with intravenous methylene blue given her cardiopulmonary compromise. Dapsone, a well-recognised cause of methaemoglobinaemia was deemed as the causative agent and was ceased immediately and indefinitely.
Despite an initial improvement of urticarial symptoms, these returned within three months. Given the previous efficacy of omalizumab, another trial was scheduled at the patient's request. She was rechallenged with 150 mg but more severe methaemoglobinaemia (38%) developed. This time, ascorbic acid and multiple doses of methylene blue were administered due to a protracted clinical course over more than 72 h.
This case provides strong temporal evidence that omalizumab can cause a dose-related acquired methaemoglobinaemia, with symptoms developing between 6 and 12 h following administration. To our knowledge, this is the first reported case of the potentially fatal condition, methaemoglobinaemia associated with omalizumab, or any monoclonal antibody.
CGR 11 NOT JUST LUPUS

PA Pucar
1,2 and P Hissaria We report the case of a 31-year-old Indian male who presented with acute renal failure and constitutional symptoms, in the context of a recent 2 month admission interstate and no significant family history. He had a diagnosis of systemic lupus erythematosus (SLE) made 2 years prior managed with mycophenolate mofetil, hydroxychloroquine and prednisolone, biopsy proven myositis (PL-12 positive) and radiological evidence of interstitial lung disease (RNP positive). His prolonged admission was with presumed first presentation lupus nephritis and sepsis, for which no organism was isolated, and was complicated by acute renal failure requiring filtration, hypocomplementaemia, haemolytic anaemia and thrombocytopaenia. Intravenous antibiotics, IVIg and three 1 g doses of rituximab were given, with failure to deplete the peripheral blood B cells. He improved with organ support in ICU and empirical antimicrobial therapy, and was discharged.
On the index admission, he presented with a creatinine of 350 mmol/L, hypocomplementaemia (C3 0.49 g/L, C4 0.09 g/L), normocytic anaemia (76 × 10 9 ) without evidence of haemolysis, mild thrombocytopaenia (117 × 10 9 ), an inflammatory response (ESR 103 mm/h) and a bland urinary sediment with a protein-creatinine ratio of 54mg/mol.
A renal biopsy demonstrated an interesting and unexpected finding, a monoclonal antibody therapy was given, and a further tissue biopsy yielded an alternative diagnosis. Method: Review of the medical records of three paediatric Royal Children Hospital patients in whom ELISA assay has identified the presence of MDA 5 antibodies.
Results: Each patient displayed a distinct clinical presentation with 2/3 developing RP-ILD. Both of these patients were of South-East Asian origin and presented under 3 years of age. One of the two patients with RP-ILD had no clinical, laboratory or radiographically features of myositis at presentation but cannot be classified as CADM due to the rapid progress of disease and death less than 6 months after diagnosis. The other patient with RP-ILD presented with classic JDM features before 12 months of age. A third patient presented at an older age with classical features of JDM and was incidentally noted to have these antibodies, without the presence of ILD.
Conclusion: Whilst the series is too small to drawn definitive conclusions it does suggest a distinct rapidly progressive phenotype in patients of South-East Asia origin. Further investigation is needed within the paediatric population to understand the true significance of this autoantibody. 
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